Navigation Links
TechConnect World 2009 Matches Tomorrow's Technology Solutions with Today's Business Needs for Clean-Technology, Biotechnology and Nanotechnology
Date:10/27/2008

The Largest Technology Matchmaking Event in the US Comes to Houston, May

3-7, 2009 at the George R. Brown Convention Center

HOUSTON, Oct. 27 /PRNewswire/ -- The Nano Science and Technology Institute (NSTI), and the Clean Technology and Sustainable Industries Organization (CTSI), today announced that the 2009 TechConnect World Conference and Expo will take place May 3-7, 2009 at the George R. Brown Convention Center in Houston, Texas.

TechConnect World is an information and networking exchange where executives from Fortune 500 companies present technological challenges in the areas of Clean-technology (such as traditional energy, renewable energy, and sustainability), Nanotechnology, and Biotechnology - to the academic and research communities - who in turn, discuss how their current research projects might be applied or adapted to address the needs presented.

"As the largest event in the United States focusing on research, development and commercialization, TechConnect World 2009 will match executives from companies like BASF, Honda, Kodak, Merck, Sanyo and many others -- with the research and business communities that are best suited to address their needs," said Bart Romanowicz, Executive Director of NSTI. "We're expecting more than 5,000 people from around the globe to join us in Houston -- making this event the largest conference and expo we've produced to date."

In addition to the Fortune 500 and research communities, TechConnect World also attracts an array of venture capital & investment firms, government agencies, and trade associations who are interested in learning how tomorrow's solutions will be applied to today's needs. The Exposition -- which features several international pavilions - is expected to host more than 400 companies, universities, equipment manufacturers and solutions providers. These exhibitors will meet with thousands of prospects and potential buyers, who come to the expo to evaluate the la
'/>"/>

SOURCE NSTI
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
6. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
7. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
8. PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso
9. Doping technique brings nanomechanical devices into the semiconductor world
10. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
11. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...wswire/--CromozInc.,locatedinResearchTrianglePark,...rdrugdeliverysysteminHyderabad,India.Thewater-solu...allsthatallowsforconjugationwithcancerdrugs,wasdev...ITT).Theconjugatedcarbonnanotubesservesasadrugdeli...hhasthepotentialtoincreasethedrugefficacy. ,, T...
(Date:11/27/2009)...wire-FirstCall/--Stallergeneshasbeen,grantedEurope...n,throughaMutualRecognitionProcedure.Germany,thefi...ferenceMemberstate. , Oralair(R)isnowregister...lic,Estonia,France,Germany,Greece,Hungary,Ireland,...lands,Poland,Portugal,Romania,Slovakia,Slovenia,a...
(Date:11/27/2009)...hanised blue dye test alternative is helping bri...nce one step closer for pharma-companies. It is a ...e developed by Sepha for use with blister packs ... and global pharma-companies such as Sanofi-Avenis...d productivity improvements on the packaging line....
(Date:11/26/2009)...new generation of ultrasmall transistors and more ...ed semiconducting nanowires are closer to reality ...e University and the University of California at L...o create nanowires with layers of different materi...which is a critical requirement for making efficie...
Breaking Biology Technology:North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3
... 29, 2009 Senomyx, Inc. (Nasdaq: SNMX ) will re... and fiscal year ending December 31, 2008 on Thurs....S. financial markets. The Company will also host...11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) t...nt will provide a business update and will discuss...
... Sigma-Aldrich (Nasdaq: SIAL ),today announced ...PC,Scientific, a leading provider of high quality ... APIs for the pharmaceutical and biotechnology ind...tific will offer Sigma-Aldrich,s,PEPscreen(R) cust...een ) to life,science researchers and pharmaceutic...
...9 Amicus Therapeutics (Nasdaq: FOLD ) will anno...esults after the regular close of markets on Thurs...ll be followed by a live conference call and webca...participants and investors may access the conferen..../Canada) or 719-325-4870 (international). A telep...
Other Biology Technology:SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009 2Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries 2Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries 3Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date 2
(Date:11/26/2009)...n,s most distinctive residents. ,Everyone wants to..., says Michelle McComb from Florida Atlantic Unive...,Perhaps their visual field has been enhanced by t...arks excellent stereovision and depth perception. ...ls of thought on this theory. In 1942, G. Walls sp...
(Date:11/26/2009)...ed deer have been caught in the hunters, sights fo...than decorative. They are lethal weapons that stag...The University of York, UK, has been intrigued by ...century and has become fascinated by the mechanica...laboration with Tomas Landete-Castillejos at the U...
(Date:11/26/2009)...ay of using recordings of birdsong to accurately m...irst time sound recordings from a microphone array...ird species, populations. Because the new techniqu...ournal of Applied Ecology , will also work with wh...ability to monitor whale and dolphin numbers. , ...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2Tough yet stiff deer antler is materials scientist's dream 2Ecologists sound out new solution for monitoring cryptic species 2Florida 26apos 3Bs Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10 Story Emergency Facility 59788 1Florida 26apos 3Bs Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10 Story Emergency Facility 59788 2Florida 26apos 3Bs Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10 Story Emergency Facility 59788 3Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 1Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 2Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 3Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 4Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 5Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 6Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 7Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 8Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 9Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 10Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 11Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 12Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 13Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 14Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 15LIVESTRONG 28R 29 Receives 24211 306 Donation from Eagle Golf 59782 1LIVESTRONG 28R 29 Receives 24211 306 Donation from Eagle Golf 59782 2
... of the worlds leading STM publishers, has signed ...ntific societies during the past half year. With ...resentative selection of Korean society journals a...blishing the increasing amount of research coming ... journals in 2008 were signed with the Korean Soci...
...rents need to be educated about managing fever in ...ectly and often unnecessarily, according to a Quee.... , QUT senior research fellow Anne Walsh conduct...nage childhood fever as part of her PhD. , Her re...iatrics and Child Health. , Ms Walsh found that, ...
...TE, Ind. - Researchers have developed a breed of A...light that decimated its population in the early 1...o-called for its picturesque form and towering hei...lew of obstacles, said a Purdue University researc...t blight, but there is a whole new set of obstacle...
Other Biology News:Fever causing headaches for Aussie parents 2Challenges remain in reintroducing American chestnut 2Challenges remain in reintroducing American chestnut 3
... expression profiling and built on the flexible an...platform. These microarrays are available as part ... Service. Probe Content The Fishes microRNA Mic...que mature sequences). The comprehensive probe con...
... expression profiling and built on the flexible an...platform. These microarrays are available as part ... Service. Probe Content The Maize microRNA Micr...ue mature sequences). The comprehensive probe cont...
...itative and qualitative capabilities of the 4000 Q...w Tempo nano MDLC System plus automation software,...validation of protein biomarkers. , , Eliminate e...electivity and sensitivity. , Build methods quick...
...nce of the LTQ, incorporating more techniques to g...ntifics innovations in ion trap technology. Therm...r that offers multiple dissociation techniques, PQ...iation (PQD) is a patented technique that eliminat...
Biology Products: